Helix BioPharma Corp.

Research Helix BioPharma Corp. (HBP0) on Bullrun: market cap EUR 62.63M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerHBP0
ExchangeF
CountryCanada
SectorHealthcare
IndustryBiotechnology
CurrencyEUR
Market capEUR 62.63M
Financial periodQ2 2026
RevenueCAD 0
Net income-CAD 671.00K
Free cash flow-CAD 880.00K

Valuation Snapshot

latest market cap is EUR 62.63M.

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-15	EUR 62.63M	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About Helix BioPharma Corp.

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer;

Related stock research

Canada stocks Canada Healthcare stocks A-Z stock index

Other Healthcare stocks

Entheon Biomedical Corp. (1XU) NANOSPHERE HEA.SCIENCES (2CG) MedMira Inc (47M) BRAXIA SCIENTIFIC CORP. (4960) WAVERLEY PHARMA INC. (5GZ) BioVaxys Technology Corp. (5LB0) GLOW LIFETECH CORP. (9DO) NERVGEN PHARMA CORP. (9UA) AbCellera Biologics Inc (ABCL) Appili Therapeutics Inc (APLI) Arch Biopartners Inc (ARCH) Aurinia Pharmaceuticals Inc (AUPH)

Frequently asked questions

What is Helix BioPharma Corp.'s market cap?

Helix BioPharma Corp.'s market capitalization is EUR 62.63M.

What does Helix BioPharma Corp. do?

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada.